Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation.
Note: You can unsubscribe from the newsletter at any time.
Advertising

Hot Products

Transcenta Received IND Clearance from US FDA for Initiating Phase I Clinical Trial for its Bi-functional Anti-PD-L1/TGF-β Antibody TST005

prnasiaApril 21, 2021

Tag: Transcenta , TST005 , PD-L1 , TGF-β